Stay updated on Pembrolizumab Combo in Endometrial Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo in Endometrial Cancer Clinical Trial page.

Latest updates to the Pembrolizumab Combo in Endometrial Cancer Clinical Trial page
- Check6 days agoChange DetectedFooter/navigation updates: added Revision: v3.3.3; removed HHS Vulnerability Disclosure and Revision: v3.3.2.SummaryDifference0.1%

- Check13 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check35 days agoChange DetectedThe page header now shows Revision: v3.3.2, replacing v3.2.0. This is a routine version update and does not change trial data.SummaryDifference0.0%

- Check42 days agoChange DetectedThe funding/operating status notice at the top of the page was removed. The rest of the page content remains unchanged.SummaryDifference0.3%

- Check63 days agoChange DetectedA new version entry was added to the record history, indicating an update to the study record. The rest of the page content remains unchanged.SummaryDifference0.0%

- Check85 days agoChange DetectedAdded a government operating status notice and a v3.2.0 revision; removed the previous v3.1.0 revision. The page now communicates potential service delays and open NIH Clinical Center status, plus the updated software version.SummaryDifference8%

- Check92 days agoChange DetectedUpdate indicates a new software version (v3.1.0) replacing the old v3.0.2; no substantive content, pricing, or availability changes are detected.SummaryDifference0.2%

Stay in the know with updates to Pembrolizumab Combo in Endometrial Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in Endometrial Cancer Clinical Trial page.